Jul. 21 at 4:11 PM
When you see
$PPBT thrown into lists alongside
$ALXO $JANX $CUE $HOWL, thatâs not analysisâitâs camouflage. Itâs a tactic to normalize the price rise by anchoring it to other names with far earlier pipelines, higher burn rates, and limited data.
đĽ Purple Biotech stands alone:
⢠Phase 2 survival data in pancreatic cancer shows up to 90% death risk reduction in biomarker-selected patients.
⢠CAPTN-3 platform is a tri-specific antibody engaging both T cells and NK cells. Solid tumor innovation with dual immune activation.
⢠Cash runway to 2026, focused pipeline, expanding IP, and a strategy thatâs quietly creating asymmetrical upside.
These drugs remains grossly undervalued vs. peers still in Phase 1 or chasing crowded targets.
Donât let ticker bundling blur the signal. This biotech isnât rising with the tideâitâs cutting through it. đ§Źđ
